Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diagnostic tool aims to end pancreatitis misdiagnosis

NCT ID NCT07536841

Diagnosis Sponsor: Military Medical Clinical Center of the Southern Region, Ukraine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new scoring system called OC26 to help doctors more accurately diagnose autoimmune pancreatitis, a condition where the immune system attacks the pancreas. Researchers will review medical data from 82 adults suspected of having the disease. If the OC26 criteria prove reliable, they could help distinguish autoimmune pancreatitis from other pancreatic conditions like cancer, leading to better treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide doctors with a more accurate and reliable tool to diagnose autoimmune pancreatitis, reducing misdiagnosis and unnecessary treatments.
What could go wrong
This is an observational study, not a treatment trial. The new criteria may not prove more accurate than existing methods, and results may not apply to all patient populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 82 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients undergoing diagnostic evaluation for suspected autoimmune pancreatitis at a tertiary referral center. The study includes both retrospective cases with complete diagnostic data and prospective participants evaluated according to the Odesa Criteria 2026 (OC26).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years) undergoing evaluation for suspected autoimmune pancreatitis. * Availability of clinical, serological, imaging, and/or histological data required for OC26 scoring. * Ability to provide informed consent (for prospective participants). Exclusion Criteria: * Confirmed alternative diagnosis explaining pancreatic findings (e.g., pancreatic cancer, acute pancreatitis of other etiology). * Incomplete diagnostic data preventing OC26 scoring. * Prior pancreatic surgery altering diagnostic interpretation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune pancreatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune pancreatitis chronic pancreatitis Immunoglobulin G4-Related Disease immunoglobulin G4-related sclerosing disease malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune pancreatitis Chronic pancreatitis IgG4-related diseases Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Military Medical Clinical Center of the Southern Region

    RECRUITING

    Odesa, Ukraine

  • Military Medical Clinical Center of the Southern Region

    RECRUITING

    Odesa, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.